Clinical Trial Update: Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma [Phase 1]

View source ↗

Summary

Open-label, sequential-dose Phase 1 study of PA5108 Latanoprost FA SR ocular implant for mild-to-moderate open-angle glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Open-angle Glaucoma

Drugs mentioned

• PA5108 Latanoprost FA SR Ocular Implant (latanoprost)

Snippet

Sponsor: PolyActiva Pty Ltd | Conditions: Open Angle Glaucoma | Phase 1 | Status: COMPLETED